Gilead Sciences Stock Investor Sentiment

GILD Stock  USD 92.41  1.06  1.16%   
About 57% of Gilead Sciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Gilead Sciences suggests that many traders are alarmed. The current market sentiment, together with Gilead Sciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Gilead Sciences stock news signals to limit their universe of possible portfolio assets.

Panic Vs Confidence

43

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Gilead Sciences' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Gilead Sciences.

Gilead Historical Sentiment

Although Gilead Sciences' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Gilead, such as negative comments on social media and news outlets, may cause fear in the market and push Gilead Sciences' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Gilead.
  

Gilead Sciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Gilead Sciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Gilead Sciences Historical Investor Sentiment

Investor biases related to Gilead Sciences' public news can be used to forecast risks associated with an investment in Gilead. The trend in average sentiment can be used to explain how an investor holding Gilead can time the market purely based on public headlines and social activities around Gilead Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Gilead Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Gilead Sciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Gilead Sciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Gilead Sciences.
21 hours ago at finance.yahoo.com         
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
Yahoo News
a day ago at investing.com         
Gilead Sciences director Jeffrey Bluestone sells 620,355 in stock
Investing News at Macroaxis
a day ago at gurufocus.com         
Gilead Sciences Inc Announces Promising Results from Phase 3 HIV Prevention Trial
Gurufocus Stories at Macroaxis
2 days ago at finance.yahoo.com         
Roche to Acquire CAR-T Cell Therapy Focused Poseida for 1.5B
Yahoo News
2 days ago at finance.yahoo.com         
Disposition of 5879 shares by Bluestone Jeffrey of Gilead Sciences at 61.17 subject to Rule 16b-3
Yahoo News
2 days ago at zacks.com         
Roche to Acquire CAR-T Cell Therapy Focused Poseida for 1.5B
zacks News
3 days ago at finance.yahoo.com         
Pulmonary Arterial Hypertension Market Is Expected To Reach Revenue Of USD 13.2 Bn By 2033, At 5.6 p...
Yahoo News
3 days ago at seekingalpha.com         
Gilead acquires investigational HIV vaccine from Spanish biotech Aelix
seekingalpha News
3 days ago at thelincolnianonline.com         
Hancock Whitney Corp Has 4.21 Million Holdings in Gilead Sciences, Inc.
news
3 days ago at thelincolnianonline.com         
Gilead Sciences, Inc. Holdings Raised by Pekin Hardy Strauss Inc.
news
few days ago at thelincolnianonline.com         
Gilead Sciences, Inc. Shares Sold by Certified Advisory Corp
news
few days ago at investing.com         
Earnings call Legend Biotech sees strong Q3 growth with CARVICTI
Investing News at Macroaxis
few days ago at nypost.com         
The 38 best books for Christmas 2024
news
few days ago at businesswire.com         
The Childrens Inn at NIH Announces 1 Million Grant From Gilead Sciences, Inc.
businesswire News
few days ago at gurufocus.com         
Gilead Announces Layoffs Amid Strong Q3 Performance, HIV Drug Sales Surge
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Gilead Sciences that are available to investors today. That information is available publicly through Gilead media outlets and privately through word of mouth or via Gilead internal channels. However, regardless of the origin, that massive amount of Gilead data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Gilead Sciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Gilead Sciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Gilead Sciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Gilead Sciences alpha.

Gilead Sciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
 
Gilead Sciences dividend paid on 27th of September 2024
09/27/2024
1
Gilead reports positive HIV PrEP data for lenacapavir
11/13/2024
2
Gileads Livdelzi Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
11/15/2024
3
TOUCH, la Alianza de Personas de la Raza Negra contra el Cncer de Seno y sus aliados presentan el centro de recursos el Oasis de TNBC para Personas de la Raza N...
11/19/2024
4
FirstLight and Maine Connectivity Authority Sign Agreement to Build 450 Miles of Fiber in Western Maine
11/20/2024
5
Cypress Capital Group Reduces Holdings in Gilead Sciences, Inc.
11/21/2024
6
Gilead Announces Layoffs Amid Strong Q3 Performance, HIV Drug Sales Surge
11/22/2024
7
Gilead Sciences, Inc. Holdings Raised by Pekin Hardy Strauss Inc.
11/25/2024
8
Gilead Sciences Inc Announces Promising Results from Phase 3 HIV Prevention Trial
11/27/2024

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges